This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D81.9 (combined immunodeficiency, unspecified) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Severe combined immunodeficiency disorder NOS, SCID NOS (unspecified), Combined immunodeficiency unspecified, Severe combined immunodeficiency NOS, combined immunodeficiency, unspecified |
| C. Adult onset | Likelihood of first onset in adulthood: very low — D81.9 is the classification for combined immunodeficiency without a detailed genetic diagnosis using current diagnostic technology, and typical SCID presents in infancy; once a molecular diagnosis is made, it may be reclassified to a detailed code. |
| 1. History | History of the SCID concept and evolution of classification. First described in the 1950s → molecular causes identified in the 1970s~90s → unclassified SCID (D81.9) is a residual category that exists because of limits of diagnostic technology, and is decreasing as classification technology advances. |
| 2. Causes | Pathogenic variants in various genes involved in T-cell and B-cell development·function (RAG1/2, IL2RG, JAK3, IL7R, ADA, DCLRE1C, PRKDC, AK2, etc.) are possible; provisionally classified as D81.9 when no molecular diagnosis has been made. |
| 3. Genetics | Overview of the full spectrum of SCID causative genes. X-linked (IL2RG, ~40~50%) or autosomal recessive. New genes continue to be discovered through WES/WGS-based diagnosis. |
| 4. General epidemiology | Overall SCID incidence about 1/50,000~1/100,000. Code D81.9 is unclassified SCID, and its proportion is decreasing as molecular diagnostic infrastructure expands. An estimated few dozen new SCID diagnoses annually in Korea. |
| 5. Pathophysiology | Gene defects at various stages of the T·B·NK-cell developmental pathways → complete loss of adaptive immunity → risk of opportunistic infections, maternal graft-versus-host reaction, and malignancy. Detailed mechanisms vary by causative gene. |
| 6. Symptoms | Recurrent opportunistic infections (PJP, CMV, candidiasis, etc.), failure to thrive, chronic diarrhea, recurrent bacterial infections, maternal GVHD (skin rash, liver function abnormalities, cytopenias, etc.). |
| 7. Signs | Severe lymphopenia (especially T cells), reduced serum immunoglobulins, absent TRECs, absent thymic shadow (chest X-ray), reduced or absent T-cell function. |
| 8. Screening | TREC-based newborn screening is most important. A TREC-negative (absent) result is linked to immediate immune function evaluation and molecular genetic testing. Expanded introduction under discussion in Korea. |
| 9. Diagnosis | Lymphocyte subsets, T-cell function tests, serum immunoglobulins, SCID gene panel NGS/WES, chest imaging. Molecular diagnosis allows reclassification from D81.9 to a specific D81.x code. |
| 10. Treatment | HSCT (curative, regardless of cause). Prophylactic anti-infective treatment, IVIG, live vaccines contraindicated. In some, enzyme replacement (ADA) or gene therapy (IL2RG, ADA deficiency) is possible. |
| 11. Prognosis | 70~90% survival with early HSCT. Varies by causative gene and donor type. Prognosis worsens with delayed diagnosis and infectious complications. An early newborn screening system is decisive for prognosis. |
| 12. Prevention | Newborn TREC screening, genetic counseling, PGT/prenatal diagnosis, infection prevention, live vaccines contraindicated, use of irradiated blood products. |
| 13. References | Pai SY et al. Transplantation outcomes for severe combined immunodeficiency 2000–2009 … and 9 other papers |
The history of severe combined immunodeficiency (SCID) begins in the early 1950s, when European pediatricians first described cases of an unusual disease in which infants died of recurrent opportunistic infections. In 1958, Robert Glanzmann and Paul Riniker of Switzerland reported cases of infant death with absent lymphocytes and severe immunodeficiency, which is recognized as the first formal description of SCID. Later, as the concepts of humoral and cellular immunity were established in the 1960s, it was understood that SCID reflects severe defects in both immune systems, and it was also called "Swiss-type agammaglobulinemia" or "lymphopenic agammaglobulinemia".
From the late 1960s through the 1970s, efforts to identify the causes of SCID became active. The discovery of ADA deficiency by Eloise Giblett in 1972 and of PNP deficiency in 1975 showed that specific enzyme deficiencies cause SCID, but these were only some of the causes of SCID. In 1986, it was established that X-linked SCID (X-SCID) is due to a defect in the interleukin-2 receptor gamma chain (IL2RG, γc chain) gene, and this was the most common type of SCID. From the 1990s, more and more SCID causative genes were identified, including JAK3, RAG1/RAG2, IL7R, ADA, and ARTEMIS.
However, despite advances in diagnostic technology, there are still SCID patients in whom no clear molecular cause is identified. ICD-10 code D81.9 is classified as "Combined immunodeficiency, unspecified", which corresponds to so-called SCID NOS (Not Otherwise Specified). D81.9 is the code applied when a clinical diagnosis of SCID has been made but the causative gene has not been identified, or at the provisional diagnosis stage. As next-generation sequencing (NGS) technology has spread, many patients previously classified as D81.9 are being reclassified through detailed genetic diagnosis to specific codes such as D81.0 (T−B+ SCID, γc deficiency), D81.1 (RAG1/2-deficient SCID), D81.2 (ADA deficiency), and D81.4~D81.8.
Despite advances in molecular diagnostic technology, there are still some SCID patients whose cause is not identified even by WES/WGS. Research to discover new SCID causative genes in these patients is actively under way worldwide, and new genes continue to be reported. In this sense, D81.9 serves as a provisional classification code for "SCID not yet explained". The introduction of newborn TREC screening has made it possible to detect SCID before symptoms appear, and early HSCT has dramatically improved prognosis. In the United States, SCID was added to the Recommended Uniform Screening Panel (RUSP) for newborn screening in 2010, and screening has since been spreading worldwide.
In terms of treatment, the world's first successful HSCT was performed in a child with SCID at the University of Minnesota in the United States in 1968, after which HSCT became established as the standard curative treatment for SCID. In 2000, the world's first successful gene therapy was reported in ADA-deficient SCID, demonstrating that gene therapy can be a treatment option for some types of SCID.
Because D81.9 (SCID NOS) is a code covering combined immunodeficiency without a molecular diagnosis, the "causes" of this category should be understood from the perspective of the full spectrum of SCID causative genes.
SCID is caused by pathogenic variants in genes essential for the development or function of T lymphocytes (and, in some cases, B lymphocytes and NK cells). The major categories of causative genes known to date, classified by immunophenotype, are as follows.
T−B+NK− SCID (absent T and NK cells, preserved B cells): the IL2RG gene (Xq13.1, X-linked, γc chain deficiency = X-SCID) is the most common, accounting for about 40~50% of all SCID. The JAK3 gene (19p13.11, autosomal recessive, JAK3 deficiency) is the next most common. In these types, disruption of the γc-JAK3 signaling pathway makes T-cell and NK-cell development impossible. In this type, B cells develop but cannot function without T-cell help.
T−B−NK+ SCID (absent T and B cells, preserved NK cells): RAG1 (11p13) and RAG2 (11p13) deficiencies are representative, accounting for about 20% of SCID. Loss of RAG protein function makes V(D)J rearrangement impossible, so no mature T cells or B cells are produced at all. DCLRE1C (ARTEMIS deficiency, 10p13) and PRKDC (DNA-PK deficiency, 8q11.21) also belong to this category.
T−B−NK− SCID (pancytopenic type): ADA (ADA deficiency, 20q13.12, about 15% of SCID) and AK2 (reticular dysgenesis, 1p34.1) are representative. In ADA deficiency, T, B, and NK cells are all affected. In AK2 deficiency (reticular dysgenesis), granulocytes as well as lymphocytes are deficient, with accompanying systemic hematopoietic failure.
T−B+NK+ SCID (isolated absence of T cells): IL7R α chain (5p13.2) deficiency is representative. IL-7 signaling is essential for T-cell development but less important for B cells and NK cells.
When WES/WGS is performed in patients provisionally classified as D81.9, new causative genes beyond these known genes are sometimes found. Since the 2010s, many new SCID-related genes have been identified, including CORO1A, ZAP70 (partial deficiency), CD3D, CD3E, CD3Z, CD3G, CD45, and LRBA. The list of SCID causative genes thus continues to expand, suggesting that ongoing updates of genetic testing are important in D81.9 patients.
To understand SCID NOS (D81.9), it is necessary to grasp the genetic diversity of SCID as a whole.
Diversity of inheritance patterns: X-SCID (IL2RG deficiency), the most common type of SCID, follows X-linked recessive inheritance and therefore presents mainly in boys. When the mother is a carrier, 50% of her sons are affected. The other SCID types (JAK3, RAG1/2, ADA, IL7R, ARTEMIS, etc.) mostly follow autosomal recessive inheritance and affect males and females equally.
Gene spectrum by immunophenotype: classifying SCID by immunophenotype (presence or absence of T cells, B cells, and NK cells) provides a useful framework for approaching the diagnosis of the causative gene. A T−B+NK− pattern points first to IL2RG/JAK3 deficiency, a T−B−NK+ pattern to RAG1/2 or ARTEMIS deficiency, a T−B−NK− pattern to ADA deficiency, and a T−B+NK+ pattern to IL7Rα deficiency. This classification system guides the next step of specific gene analysis.
Molecular diagnostic strategy: currently, primary immunodeficiency gene panels using next-generation sequencing (NGS) (covering 30~300 or more genes), or whole-exome sequencing (WES) and whole-genome sequencing (WGS), have become the standard molecular tools for SCID diagnosis. These have made it possible to identify the causative gene in many patients previously classified as D81.9. The pathogenicity of new gene variants is assessed according to ACMG guidelines and, if needed, confirmed by functional studies (cell-based assays, animal models, etc.). WGS has the advantage of covering regulatory sequences outside coding regions, structural variants (SV), and copy number variants (CNV), and can identify variants not found even by WES.
The overall incidence of SCID worldwide is estimated at 1 per 50,000~100,000 births. US PIDTC (Primary Immune Deficiency Treatment Consortium) data report about 1/58,000, and European ESID registry data about 1/75,000~1/100,000. As for sex distribution, because of the X-linked nature of X-SCID (the most common type), about 55~65% of all SCID patients are boys.
Patients registered under code D81.9 represent the proportion of all SCID without a molecular diagnosis, which varies with each country's level of molecular diagnostic infrastructure. In countries with highly advanced medical systems, access to WES/WGS is high and the proportion of D81.9 is relatively low, whereas in countries with limited molecular diagnostic infrastructure the proportion of D81.9 is high. Recent data from international SCID research networks (PIDTC, ESID, ICHI) report that about 10~20% of SCID patients remain of unknown cause after WES.
In Korea, considering the annual number of births (about 200,000~300,000), 3~6 new SCID patients are estimated to occur annually. In Health Insurance Review & Assessment Service (HIRA) claims data for codes D81.0~D81.9, patients of all SCID types are registered at a level of a few dozen per year, and among these, D81.9 is used when no molecular diagnosis has been made or as a provisional code early in diagnosis.
The pathogenesis of SCID NOS (D81.9) differs in detail according to the causative gene, but the common core is complete blockade of T-lymphocyte development or function and the resulting combined loss of cellular and humoral immunity.
T cells arise from bone marrow-derived common lymphoid progenitors (CLP), which migrate to the thymus and, supported by the intrathymic microenvironment, undergo a multistep maturation process to differentiate into CD4+ or CD8+ T cells. A defect at any stage of this process results in SCID. At early stages, IL-7/IL-7R signaling (IL7R deficiency), γc chain/JAK3 signaling (IL2RG or JAK3 deficiency), and ADA activity (ADA deficiency) are involved. At intermediate stages, V(D)J rearrangement of TCR genes (RAG1/2, ARTEMIS deficiency) is essential, and this rearrangement generates diverse T-cell clones. After positive·negative selection in the thymus, mature T cells are released to the periphery. Whichever stage of this pathway is blocked, the end result is absence of mature T cells.
Without T cells, cell-mediated immunity (CMI) is lost and defense against intracellular pathogens (viruses, fungi, intracellular bacteria including mycobacteria, protozoa) becomes impossible. At the same time, without T-cell help B cells cannot produce effective IgG antibodies against T-cell-dependent antigens, so humoral immune function is also impaired. The result is complete loss of all adaptive immunity, leaving the patient extremely vulnerable to opportunistic pathogens. In addition, in types in which NK cells are also absent (e.g., IL2RG, JAK3, ADA deficiency), the NK-cell surveillance function of innate immunity is also impaired.
Because SCID infants lack immune surveillance, maternal T lymphocytes that have crossed the placenta can engraft in the fetus and newborn and cause graft-versus-host disease (GvHD). This is the maternal engraftment GvHD observed in SCID newborns, presenting as skin rash, liver function abnormalities, and cytopenias. When unexplained GVHD-like symptoms appear in a SCID infant, this becomes an important diagnostic clue.
The clinical symptoms of SCID NOS (D81.9) are shared with other SCID types and all stem from severe combined immunodeficiency.
Severe opportunistic infections typically occur within 3~6 months of birth. The immunodeficiency becomes apparent as maternal IgG is depleted. The most common and lethal opportunistic infections include Pneumocystis pneumonia (PJP), candidiasis (oral, esophageal, cutaneous), CMV infection (pneumonia, retinitis, hepatitis), EBV-related infections, and disseminated varicella. Disseminated BCG (BCGosis) after live BCG vaccination is a strong clue to SCID. Bacterial infections (pneumococcus, Salmonella, Pseudomonas) also recur.
Chronic diarrhea, malabsorption, weight loss, and failure to thrive (FTT) are present. Chronic diarrhea is caused by enteric viruses (rotavirus, norovirus) and parasites (Cryptosporidium, Giardia).
If a non-infectious skin rash (erythematous, scaly), jaundice, liver function abnormalities, or cytopenias (pancytopenia or hemolytic anemia) appear within a few weeks of birth, graft-versus-host reaction due to maternal T cells is suspected. Maternal graft-versus-host reaction can be the first clinical clue to SCID.
The key laboratory finding of SCID is severe T-cell deficiency, and B-cell and NK-cell counts vary by type.
On peripheral blood flow cytometry, the absolute T-cell count (ATC) is markedly reduced or absent (normal infant ATC > 3,000/μL). An ATC < 300/μL is in the typical SCID range. The immunophenotype (T/B/NK cell counts) varies by causative gene, appearing as T−B+NK−, T−B−NK+, T−B−NK−, and so on, and this pattern provides an important clue for inferring the causative gene. T-cell function testing (PHA proliferation response) shows a marked reduction or absence. Serum immunoglobulins may appear normal early because of residual maternal IgG, but fall sharply at 3~6 months of age. Absent thymic shadow on chest X-ray. Absent or markedly reduced TRECs on TREC analysis. When maternal GVHD is present, skin biopsy shows allogeneic T-cell infiltration, and blood testing identifies lymphocytes of maternal origin.
The most important tool for early detection of all SCID types, including SCID NOS, is TREC-based newborn screening. TRECs are small circular DNA molecules generated during TCR gene rearrangement as T cells mature in the thymus, and are a surrogate marker of new thymic T-cell output. In SCID, thymic function is lost and T cells are not produced, so TRECs are also absent. TREC testing is performed by real-time PCR on dried blood spots (DBS) collected 24~48 hours after birth. When a negative or markedly reduced TREC result is confirmed, it is linked immediately to lymphocyte subset testing (T/B/NK cell counts), T-cell function testing, immunoglobulin quantification, and primary immunodeficiency gene panel NGS. In the United States, TREC-based SCID newborn screening has been mandatory in all states since 2010, and after introduction of TREC screening, the proportion of SCID diagnosed before symptom onset rose from 50% to over 80%. In Korea, TREC newborn screening has not yet been designated a mandatory national screening item but is performed at some medical institutions, and a policy review of national introduction is under way.
Diagnosis of SCID proceeds in stages: clinical suspicion → immunological confirmation → molecular genetic confirmation. Because D81.9 is a code applied at the stage before molecular confirmation, reclassification to a specific code through molecular diagnosis is recommended whenever possible.
Step 1: lymphocyte count and T/B/NK subsets: confirm a reduced absolute lymphocyte count on complete blood count. Measure absolute counts and proportions of T (CD3+, CD4+, CD8+), B (CD19+), and NK (CD16+/CD56+) cells by flow cytometry. Identify the immunophenotype pattern (T-B+NK-, T-B-NK+, T-B-NK-) to predict the causative gene.
Step 2: T-cell function testing: confirm a markedly reduced or absent proliferative response to PHA and anti-CD3 stimulation. T cells with an abnormally high TREC ratio may be of maternal origin and need to be distinguished.
Step 3: serum immunoglobulins: quantify IgG, IgA, and IgM. Because early IgG may appear normal owing to residual maternal IgG, serial follow-up over time is important.
Step 4: molecular genetic confirmation: primary immunodeficiency gene panel NGS or WES simultaneously analyzes variants in known SCID genes such as IL2RG, JAK3, RAG1, RAG2, ADA, IL7R, DCLRE1C, PRKDC, and AK2. If panel NGS is negative, testing is expanded to WES/WGS to search for new variants. After molecular confirmation, the case is reclassified from D81.9 to the corresponding specific code (D81.0~D81.8).
Step 5: confirmation of maternal GVHD: when there are GVHD findings such as skin rash, HLA analysis of blood lymphocytes is used to identify lymphocytes of maternal origin.
The curative treatment for all SCID types, including SCID NOS, is hematopoietic stem cell transplantation (HSCT). Regardless of the causative gene, HSCT is the curative goal, and the earlier it is performed, the better the prognosis.
HLA-matched sibling donor (MSD) transplantation is ideal, but because this is unavailable for most patients, transplantation using HLA-matched unrelated donors (MUD), haploidentical donors, or HLA-matched unrelated cord blood is also attempted. Recently, with advances in T-cell depletion techniques (TCRαβ/CD19-depleted haploidentical HSCT, CD34 selection, etc.), outcomes of haploidentical donor transplantation have also improved greatly. Whether to use conditioning and its intensity (myeloablative vs. reduced-intensity) are determined by the causative gene, immunophenotype, and donor type.
In ADA-deficient SCID, PEG-ADA (polyethylene glycol-conjugated bovine ADA) is available as enzyme replacement therapy. It is used as bridging therapy before HSCT or as an alternative when HSCT is not possible. In X-SCID (IL2RG deficiency) and ADA deficiency, autologous hematopoietic stem cell gene therapy based on retroviral or lentiviral vectors has been clinically established. For ADA deficiency, lentiviral vector-based gene therapies (Strimvelis, EMA approval 2016; Libmeldy, EMA approval 2021) are licensed in Europe.
Standard supportive care consists of TMP-SMX (PJP prophylaxis), antifungals, IVIG, CMV monitoring and preemptive ganciclovir/valganciclovir, an isolation environment (air filtration, visitor restriction), absolute contraindication of live vaccines, and use of irradiated, CMV-negative, leukocyte-filtered blood products for transfusion.
The prognosis of SCID as a whole, including SCID NOS, depends decisively on whether diagnosis is early and on the timing and conditions of HSCT. In a large multicenter study by the PIDTC (Primary Immune Deficiency Treatment Consortium) (published in NEJM in 2014), the 5-year overall survival of 240 SCID patients who received HSCT was reported to be about 72%.
Early HSCT (before infection): in patients diagnosed through newborn screening before symptom onset who received HSCT without infectious complications, 5-year survival is markedly high at over 90%. This directly demonstrates the clinical value of SCID newborn screening. HSCT after infection: when HSCT is performed after severe opportunistic infection, survival drops to about 50~70%. Performing HSCT while PJP or CMV infection is active greatly increases transplant-related mortality. Prognosis by donor type: 5-year survival is best after HLA-matched sibling donor transplantation at about 82%, with about 67% reported for HLA-matched unrelated donor transplantation and about 62% for haploidentical donor transplantation. However, with advances in transplant technology, outcomes of haploidentical transplantation continue to improve. After successful HSCT, long-term follow-up is needed for chronic GVHD, PTLD, endocrine dysfunction (gonadal, thyroid), growth and development, neurodevelopment, and more.
Prevention of SCID consists of reducing genetic risk (primary), early diagnosis and infection prevention (secondary), and minimizing complications (tertiary). Introduction of newborn TREC screening is the most powerful secondary prevention measure among these.
After carrier identification in families of affected children, options for PGT or prenatal genetic diagnosis are offered. In X-SCID families, maternal carrier status is checked prenatally in conjunction with determination of fetal sex.
TREC-based newborn screening detects SCID early before symptom onset, allowing immediate protective measures (isolation, infection-prevention medications, preparation for HSCT). National TREC screening needs to be actively pursued in Korea. After diagnosis, live vaccines (including BCG) are absolutely prohibited, and irradiated blood products are used for transfusion.
After successful HSCT, T-cell counts/function, immunoglobulins, vaccine antibody titers, chronic GVHD, PTLD, endocrine function, growth, and neurodevelopment are followed regularly. Psychological support for the family and connections to specialized patient organizations (Korean Primary Immunodeficiency Patients' Association, PIDTC, Jeffrey Modell Foundation, ESID) are provided.
Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. New England Journal of Medicine. 2014;371(5):434–446. DOI: 10.1056/NEJMoa1401177. PMID: 25075835.
Puck JM. Population-based newborn screening for severe combined immunodeficiency: steps toward implementation in the United States. Journal of Allergy and Clinical Immunology. 2007;120(4):760–768. DOI: 10.1016/j.jaci.2007.08.067. PMID: 17931559.
Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–738. DOI: 10.1001/jama.2014.9132. PMID: 25138334.
Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe combined immunodeficiencies and related disorders. Nature Reviews Disease Primers. 2015;1:15061. DOI: 10.1038/nrdp.2015.61. PMID: 27188754.
Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.
Dvorak CC, Haddad E, Buckley RH, et al. The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era. Blood Advances. 2019;3(19):2918–2926. DOI: 10.1182/bloodadvances.2019000882. PMID: 31575493.
Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase–deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Science Translational Medicine. 2011;3(97):97ra80. DOI: 10.1126/scitranslmed.3002716. PMID: 21865537.
Casanova JL, Conley ME, Seligman SJ, et al. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. Journal of Experimental Medicine. 2014;211(11):2137–2149. DOI: 10.1084/jem.20140520. PMID: 25311508.
Gennery AR, Cant AJ. Diagnosis of severe combined immunodeficiency. Journal of Clinical Pathology. 2001;54(3):191–195. DOI: 10.1136/jcp.54.3.191. PMID: 11253130.
Bousfiha A, Jeddane L, Picard C, et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. Journal of Clinical Immunology. 2020;40(1):66–81. DOI: 10.1007/s10875-019-00722-4. PMID: 32048120.